Conference Recap

Highlights in Non–Small Cell Lung Cancer From ASCO 2020


 

Presented during the ASCO 2020 plenary session, the results of the phase 3 ADAURA trial will prove practice-changing, according to Dr. Mark Kris of Memorial Sloan Kettering Cancer Center. Over 600 patients whose resected tumors were found to have EGFR mutations were treated with osimertinib. The results more than doubled disease-free survival rates, from 44% to 90% at 2 years.

Among other adjuvant trials, the phase 2 VISION study looked at tepotinib, a once-daily, highly selective oral MET inhibitor. The study showed durable responses coupled with acceptable side effects. The drug has been given fast-track status by the US Food and Drug Administration.

Dr. Kris notes that the DESTINY study introduces trastuzumab deruxtecan, an antibody- drug conjugate, as a promising new class of drugs for lung cancer patients. Interim results presented at ASCO further support the HER2 mutation as another potential target for patients with lung cancer.

Finally, the phase 2 CITYSCAPE study provides preliminary evidence for a new checkpoint inhibitor. The monoclonal antibody tiragolumab was developed to block TIGIT. The study showed that the combination of tiragolumab and atezolizumab can improve both rates of response and time to disease recurrence — results Dr. Kris considers encouraging for patients with advanced lung cancer.

Mark G. Kris, MD

Mark G. Kris, MD, Professor, Department of Medicine, Weill Cornell Medical College; Attending Physician, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

Recommended Reading

Trastuzumab deruxtecan proves active in HER2-mutated NSCLC
MDedge Hematology and Oncology
Germline testing in advanced cancer can lead to targeted treatment
MDedge Hematology and Oncology
‘Promising’ durvalumab results spark phase 3 trial in mesothelioma
MDedge Hematology and Oncology
Pembrolizumab plus EP gives slight PFS edge in ES-SCLC
MDedge Hematology and Oncology
TKI plus SBRT tops TKI alone for oligometastatic EGFRm NSCLC
MDedge Hematology and Oncology
Tepotinib elicits responses in METex14 NSCLC
MDedge Hematology and Oncology
No OS benefit with gefitinib vs. chemo for EGFR+ NSCLC
MDedge Hematology and Oncology
‘Hospital at home’ cuts ED visits and costs for cancer patients
MDedge Hematology and Oncology
CheckMate 9LA: ‘Doing better’ for stage IV/recurrent NSCLC
MDedge Hematology and Oncology
Immunotherapy combo improves ORR, PFS in PD-L1+ NSCLC
MDedge Hematology and Oncology